Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
July 09 2020 - 7:30AM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader
in gene and cell therapy, today announced the appointment of
Michael Amoroso as Senior Vice President and Chief Commercial
Officer (CCO), effective immediately. Mr. Amoroso brings to Abeona
over 20 years of product commercialization experience in the
biotechnology and pharmaceutical industries, most recently as
Senior Vice President and Head of Worldwide Commercial, Cell
Therapy at Kite, a Gilead Company.
Mr. Amoroso will have overall responsibility for
building the Company’s commercial organization, developing the
commercialization strategy for EB-101, its autologous,
gene-corrected cell therapy for the treatment of recessive
dystrophic epidermolysis bullosa (RDEB) and its lead product
candidate, as well as leading pre-commercial planning for its
investigational adeno-associated virus vector (AAV)-based gene
therapies.
“Michael is a highly accomplished commercial leader
with a focus on cell and gene therapies and a proven track record
of launching innovative drugs for rare diseases,” said João
Siffert, M.D., Chief Executive Officer of Abeona. “As we advance
our pivotal Phase 3 VIITAL™ study of EB-101 in RDEB, Michael’s
proven track record in commercialization, supply chain management
for personalized, autologous cell therapies, experience in
developing novel launch plans, working closely with governments
around the world to ensure patients have access, and ability for
building commercial and organizational capabilities will lay the
groundwork for our potential go-to-market strategy for EB-101.
Furthermore, his history of integrating commercial perspective into
pipeline programs will be instrumental in positioning our
investigational AAV gene therapies to shape the treatment paradigm
for patients with MPS IIIA, MPS IIIB, and other rare genetic
diseases.”
Prior to joining Abeona, Mr. Amoroso held various
senior level commercial positions at leading biopharmaceutical
companies, including Kite, Eisai Inc., Celgene Corporation (now a
subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite,
he was responsible for the company’s worldwide commercial
organization leading the commercialization efforts for the
autologous CAR T-cell therapy, YESCARTA®, and the future cell
therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice
President, Americas for Eisai’s Commercial Oncology Business Group,
where he was accountable for teams charged with creating and
driving commercial strategy and implementation for the company’s
approved products and earlier-stage assets. Previously, Mr. Amoroso
worked at Celgene for six years in several commercial roles before
serving as the organization’s Commercial Lead for CAR T-cell
therapy programs. In this capacity, he helped Celgene develop an
organizational model to commercialize cell therapies including
specialized manufacturing and customer services for patients with
lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held
various marketing and sales leadership positions over his 10-plus
year tenure at Sanofi. Mr. Amoroso earned his M.B.A. in Management
from the Stern School of Business, New York University, and his
B.A. in Biological Sciences, summa cum laude, from Rider
University.
About Abeona Therapeutics Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company
developing gene and cell therapies for serious diseases. Abeona’s
clinical programs include EB-101, its autologous, gene-corrected
cell therapy for recessive dystrophic epidermolysis bullosa in
Phase 3 development, as well as ABO-102 and ABO-101, novel
AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS
IIIA and MPS IIIB), respectively, in Phase 1/2 development. The
Company’s portfolio of AAV-based gene therapies also features
ABO-202 and ABO-201 for CLN1 disease and CLN3 disease,
respectively. Abeona’s library of novel, next-generation AIM™
capsids have shown potential to improve tropism profiles for a
variety of devastating diseases. Abeona’s fully functional, gene
and cell therapy GMP manufacturing facility produces EB-101 for the
pivotal Phase 3 VIITALTM study and is capable of clinical and
commercial production of AAV-based gene therapies. For more
information, visit www.abeonatherapeutics.com.
Forward-Looking Statements This
press release contains certain statements that are forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and that involve risks and uncertainties. These
statements include statements about the Company’s clinical trials
and its products and product candidates, future regulatory
interactions with regulatory authorities, as well as the Company’s
goals and objectives. We have attempted to identify forward
looking statements by such terminology as “may,” “will,” “believe,”
“estimate,” “expect,” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, numerous risks and uncertainties,
including but not limited to the potential impacts of the COVID-19
pandemic on our business, operations, and financial condition,
continued interest in our rare disease portfolio, our ability to
enroll patients in clinical trials, the outcome of any future
meetings with the U.S. Food and Drug Administration or other
regulatory agencies, the impact of competition, the ability to
secure licenses for any technology that may be necessary to
commercialize our products, the ability to achieve or obtain
necessary regulatory approvals, the impact of changes in the
financial markets and global economic conditions, risks associated
with data analysis and reporting, and other risks as may be
detailed from time to time in the Company’s Annual Reports on Form
10-K and quarterly reports on Form 10-Q and other periodic reports
filed by the Company with the Securities and Exchange
Commission. The Company undertakes no obligation to revise
the forward-looking statements or to update them to reflect events
or circumstances occurring after the date of this presentation,
whether as a result of new information, future developments or
otherwise, except as required by the federal securities laws.
Investor Contact:Greg Gin VP,
Investor Relations Abeona Therapeutics +1 (646)
813-4709ggin@abeonatherapeutics.com
Media Contact:Scott Santiamo
Director, Corporate Communications Abeona Therapeutics +1 (718)
344-5843 ssantiamo@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024